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DOI 10.1016/j.ccr.2010.10.034SUMMARYMaintenance of genomic integrity is essential for adult tissue homeostasis and defects in the DNA-damage
response (DDR) machinery are linked to numerous pathologies including cancer. Here, we present evidence
that the DDR exerts tumor suppressor activity in gliomas. We show that genes encoding components of the
DDR pathway are frequently altered in human gliomas and that loss of elements of the ATM/Chk2/p53
cascade accelerates tumor formation in a glioma mouse model. We demonstrate that Chk2 is required for
glioma response to ionizing radiation in vivo and is necessary for DNA-damage checkpoints in the neuronal
stem cell compartment. Finally, we observed that the DDR is constitutively activated in a subset of human
GBMs, and such activation correlates with regions of hypoxia.INTRODUCTION
The gliomas are a large group of brain cancers that include
astrocytomas, oligodendrogliomas, and oligoastrocytomas.
Glioblastoma multiforme (GBM), the highest grade of malignant
astrocytomas (WHO Grade IV), is the most common and lethal
primary central nervous system (CNS) tumor in adults. Despite
the recent advances in treatment modalities, GBM patients
generally respondpoorly to all therapeutic approaches and prog-
nosis remains dismal. On amolecular basis, a decade of studies,
including the most recent large-scale genomic analysis (The
Cancer Genome Atlas Research Network, 2008; Parsons et al.,
2008), has underlined the complexity and heterogeneity of
genetic events that characterize the glioblastoma genome, but
the mechanisms responsible for the variability in radiation
response remain elusive.Significance
Glioblastoma mutliforme (GBM) is the most aggressive and let
decades of efforts, GBMs patients remain refractory to standar
the mechanisms responsible for this poor treatment response
Here, we show that some of the elements of the DNA damag
formation in a glioma mouse model. Furthermore, we demons
required for glioma radiation sensitivity, suggesting that the inte
sion and for irradiation response.
CanGBMs are divided in two subtypes on the basis of clinical
history: ‘‘primary GBMs’’ that arise de novo, with no evidences
of precursor lesions, and ‘‘secondary GBMs,’’ evolving from
a lower grade tumor over time. Histologically, GBMs are charac-
terized by tumor cells invading adjacent normal brain paren-
chyma, vascular proliferation and by the presence of area of
necrosis and hemorrhage. Necrotic regions are typically
surrounded by dense cellular zones, normally referred as to
pseudopalisades. The origin of these structures is still currently
debated, but they are of central importance to the malignant
behavior of GBMs (Brat et al., 2004).
Preservation of genomic integrity is an essential process for
cell homeostasis and defects in the DNA-damage response
(DDR), a complex network of proteins required for cell-cycle
checkpoint and DNA repair, have been associated with tumori-
genesis. In response to DNA damage, cells activate the sensorhal tumor of the central nervous system in the adult. Despite
d therapies and have a very low survival rate. Understanding
is one of the primary goals in the brain tumor research field.
e response (DDR) pathway are required to suppress tumor
trate that Chk2, one of the key components of the DDR, is
grity of this pathway is instrumental both for tumor suppres-
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Mutation CNA (loss)
N. of patients Case ID Type AA change
ATR 1 (0.6%) TCGA-02-0010 Nonsense R2533* 17 (6.3%)
ATM 2 (1.3%) TCGA-02-0010 Missense G138R 33 (12%)
2 mutations Missense V245A
TCGA-02-0114 Missense R2912K
CHEK1 2 (1.3%) TCGA-06-0145 Missense R160H 35 (13%)
TCGA-02-0043 Splice site
CHEK2 n/d - - - 60 (22%)
Figure 1. CHEK2 Is Commonly Altered in GBM
(A) Table of somatic mutations (n = 158) (see also Table S1)
and copy number alteration (CNA; only chromosomal copy
loss are shown) (n = 272) assessed in primary GBM
samples of TCGA. CHEK2 mutation frequency couldn’t
be determined due to technical reasons (see the text for
details).
(B) CHEK2 expression is significantly decreased in tumors
with copy loss (p = 3.5e-9, Student’s t test).
(C) Venn diagram representing event of loss/mutation of
TP53, amplification of MDM2/4 and loss/mutation of
CHEK2 (unaltered = 126).
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DNA Damage Response and Gliomagenesiskinases ATM, ATR, and DNA-PK (Durocher and Jackson, 2001;
Shiloh, 2003) that in turn phosphorylate multiple downstream
substrates, including the effector kinases Chk1 andChk2 (Bartek
and Lukas, 2003; Stracker et al., 2009), resulting in cell-cycle
checkpoint initiation and/or apoptosis. Markers of a constitu-
tively active DDR have been described in many types of malig-
nant lesions in different tissues (Bartkova et al., 2005; Gorgoulis
et al., 2005; Nuciforo et al., 2007). The DDR acts as a barrier
against tumor progression, where precancerous lesions must
inactivate p53 or other elements of the DDR to proceed to
amore aggressive status (Bartkova et al., 2005, 2006). A system-
atic approach to analyze the putative tumor suppressor activity
of the DDR in gliomas has not been undertaken. Furthermore,
given that radiation is the standard therapy for GBM patients,
understanding the tumor-specific abnormalities of the DDR
machinery may be of important value to design patient-specific
therapies.
In this study, we performed a detailed analysis of the genetic
alteration in GBMs of genes encoding DDR components using
the data available through The Cancer Genome Atlas (TCGA)
consortium. We further focused on the tumor suppressor activity
of the ATM/Chk2/p53 pathway in a gliomamousemodel, andwe
investigated the contribution of loss of the Chk2 checkpoint
kinase to the radiation resistance of GBMs.RESULTS
Genetic Loss of Function of the DDR in Human GBMs
Recent large-scale genomic analyses of GBM have identified
a diversity of recurrent mutations and chromosomal copy
number alterations (CNA) affecting genes involved in multiple620 Cancer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier Inc.signaling pathways (The Cancer Genome Atlas
Research Network, 2008; Parsons et al., 2008).
We now performed an analysis of TCGA data
set for GBM, looking at genes encoding key
components of the DDR and we found that
3.2% of tumors showed somatic mutations in
ATR, ATM, or CHEK1 (Figure 1A; see Table S1
available online). The exact frequency of CHEK2
mutations is unknown at this time because
many of the mutations initially described in the
TCGA data set have not been reconfirmed by
secondary analysis (Table S1).
Genomic loss of at least one copy of ATR,
ATM, CHEK1, or CHEK2 was found in 36% of
GBM samples in TCGA. Loss among the four genes was signifi-
cantly higher than background as determined by random
sampling (p = 0.0146, 10,000 iterations) (see Supplemental
Experimental Procedures). Among these four DDR components
analyzed, CHEK2 was the most commonly lost (22%) and copy
number loss was associated with significantly lower gene
expression (Figure 1B). Only a small percentage of patients that
had CHEK2 deletions presented concomitant alterations of the
other DDR components under investigation: 13.3% (8/60) for
ATM, 10% (6/60) for ATR, and 11.6% (7/60) for CHEK1 (Table
S2). On the other hand, approximately 50% of GBM patients
with CHEK2 alterations also carried defect in the p53 signaling
pathway (such as TP53 mutation/loss or amplifications of
MDM2/4, both well-known p53 inhibitors), suggesting that these
genetic events are not mutually exclusive in gliomas (Figure 1C).
The ATM/Chk2/p53 Loss of Function Accelerates GBM
Formation in Mice
The frequent alterations of DDR components in human GBMs
suggested a putative tumor suppressor activity of this pathway
in the brain. Therefore, to directly demonstrate a role of loss of
DDR core elements (ATM, CHK2, and p53) in glioma formation,
we employed the RCAS/tv-a system, that uses a specific avian
leukosis virus (RCAS) to mediate gene transfer into somatic cells
transgenic for its receptor (tv-a). In this study, we used Nestin-
tv-a (Ntv-a) mice that express the tv-a receptor under the control
of the nestin promoter, a marker of neural/glial stem and progen-
itor cells (Holland et al., 1998). Newborn mice were injected with
cells producing the RCAS retroviruses carrying the platelet-
derived growth factor-B (PDGFB) (Shih et al., 2004).
In Ntv-a mice, loss of either both copies or a single copy of
Chk2 significantly accelerates PDGF-induced glioma formation,
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Figure 2. The ATM/Chk2/p53 Cascade Prevents GBM Formation in Mice
(A and B) Kaplan-Meier survival curves of PDGF-induced gliomas in Nestin-tva mice of the indicated genotypes; log rank p values have been measured with the
Mantle-Cox test.
(C) Top panel, H&E staining of a RCAS/PDGF-induced GBM (left), inset shows pseudopalisading necrosis (black arrows) and microvascular proliferation (yellow
arrows) (right); bottom panel, IHC staining with anti-Olig2 (left) and anti-GFAP (right) of the GBM showed above. Scale bars, 100 mm.
(D) Graph showing the percentage of Grade II–IV tumors for the indicated genotypes.
(E) Table showing the number of Grade IV tumors (GBM)/total tumors; p values were measured versus wild-type mice using the Fisher’s exact test.
See also Figure S1.
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DNA Damage Response and Gliomagenesiswith the wild-type mice having an average survival of over
90 days, Chk2 null mice of 34 days (p < 0.0001, log rank test)
and heterozygous of 55 days (p = 0.0036, log rank test) (Fig-
ure 2A). Notably, loss of heterozigosity (LOH) was not detected
in Chk2+/ gliomas (Figure S1A); however, two of four tumors
analyzed showed lower expression of Chk2 mRNA when
compared with the normal contralateral side of the brain (Fig-
ure S1B), suggesting that other mechanisms than genomic
loss can lead to inactivation of the remaining wild-type allele.
Chk2 is known to be required for the p53-dependent apoptotic
response to radiation (Hirao et al., 2000, 2002; Takai et al., 2002).
In order to analyze the role of p53 in Chk2-mediated tumor
suppression, we crossed Ntv-a Chk2/ mice with p53/
mice and noted that PDGF-induced gliomas arise with a similar
latency in both genetic backgrounds (Figure 2A). Furthermore,
the loss of a single p53 allele did not further accelerate glioma
formation when Chk2 is already partially inactivated (Chk2+/).
Both p53+/ and Chk2+/;p53+/ genetic backgrounds showed
a PDGF-induced glioma-free survival very similar to the
Chk2+/ background, suggesting that Chk2 and p53 are epistatic
in the suppression of glioma formation.
ATM kinase is required for Chk2 activation and acts in concert
and in parallel with Chk2 in DNA damage checkpoint modulation
(Matsuoka et al., 1998; Stracker et al., 2007); therefore, we deter-Canmined if ATMwas also required to suppress PDGF-induced glio-
magenesis. Indeed, loss of a single copy or both copies of ATM
significantly accelerates PDGF-induced glioma formation, with
Atm+/+ mice having an average survival of 91 days, Atm+/ of
61 days (p = 0.0023, log rank test) and Atm/ of 58.5 days
(p = 0.019, log rank test) (Figure 2B). No LOH was detected in
Atm+/ gliomas (Figure S1C).
Gliomas of all genotypes expressed Olig2 throughout the
tumor mass, while GFAP-positive cells were restricted to the
area adjacent to tumor vessels (Figure 2C, bottom panels) and
along the tumor/normal border (data not shown). The tumors of
the different genotypes were then classified using the World
Health Organization (WHO) grading system: Grade IV, also
known as GBM (presence of microvascular proliferation, MVP,
and pseudopalisading necrosis), Grade III (presence of MVP
only), and Grade II (absence of both MVP and pseudopalisading
necrosis) (Figure S1D). GBMs arise with higher frequency in
Chk2 null (72%) (p < 0.0001, Fisher’s exact test), p53 null
(100%) (p = 0.0029, Fisher’s exact test), and Atm null mice
(83%) (p = 0.0002, Fisher’s exact test) compared with wild-
type mice (19%) (Figures 2D and 2E), suggesting that the
ATM/Chk2/p53 pathway is required to constrain the tumor
progression to a more malignant phenotype. Moreover,
despite having a similar glioma free survival, p53+/ andcer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier Inc. 621
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Figure 3. Chk2 Is Required for Radiation Response
in Gliomas In Vivo
(A and B) Percentage of (A) TUNEL (24 hr post 10 Gy IR)
and (B) pH 3 (3 and 24 hr post 10 Gy IR) positive glioma
cells in tumor-bearing mice of the indicated genotype;
Student’s t test (A) **p = 0.0023, ***p = 0.007 and (B)
##p = 0.0089 (Chk2/ versus WT). Data are presented
as mean ± SD of three tumors for each group.
(C and D) Kaplan-Meier survival curves of RCAS/PDGF-
induced gliomas in Ntv-a and Ink4a/Arf/ and Ntv-a
Chk2/ mice, respectively; black arrows indicate the
day of exposure to 10 Gy IR. Log rank p values have
been measured with the Mantle-Cox test.
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DNA Damage Response and GliomagenesisChk2+/;p53+/mice developGBMswith a higher frequency than
the Chk2+/ mice (75% and 85% versus 40%). These data
suggest that loss of Chk2 does not completely phenocopy p53
loss with regards to tumor formation, and may explain the
concurrent alteration of TP53 and CHEK2 in a subset of human
GBMs.
Loss of Chk2 Potentiates GBMs Radiation Resistance
In Vivo
Radiotherapy and chemotherapy are the standard treatments for
GBMs patients; however, the treatment outcomes are variable
and most patients respond poorly to these treatments. Ionizing
radiation (IR) and radiomimetic drugs lead to the formation of
double-strand DNA breaks (DSBs) that are responsible for the
establishment of the DDR. To determine if loss of Chk2 contrib-
utes to the poor response of glioma to IR, we analyzed the
outcome of radiation in the Chk2/ tumor-bearing mice.
As controls, we used both wild-type and Ink4a/Arf null mice
(Dai et al., 2001), since deletion of the INK4a/ARF locus is one
of the most frequent events that leads to p53 pathway inactiva-
tion in human glioma.
To examine the IR response of glioma in vivo, glioma-bearing
mice were exposed to ten Gy IR and apoptosis and G2/M arrest
were measured after 24 hr. As shown in Figure 3A, upon IR,
Ink4a/Arf null mice showed a nonsignificant reduction of TUNEL-
positive tumor cells compared with wild-type mice (10% and
20%, respectively, p > 0.05, Student’s t test). By contrast,
Chk2 null mice showed significantly reduced numbers of
apoptotic cells (approximately 3%), compared both with wild-
type mice (p = 0.0023, Student’s t test) and Ink4a/Arf null (p =
0.0007, Student’s t test). Moreover, while the number of dividing622 Cancer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier Inc.tumor cells (phospho-Histone H3 [pH3]) are
nearly undetectable 3 hr post-IR in all the
different genetic background analyzed, only
the Chk2 tumors have a similar number of
dividing cells to the control nonirradiated mice
24 hr post-IR (Figure 3B).
We then examined the long-term effect of
ionizing radiation in the Chk2/ and Ink4a/
Arf/ GBM mouse models. Of note, we did not
include wild-type mice in this experiment due
to their much lower tumor incidence and longer
survival. Newborn mice were injected with
RCAS/PDGF and 18 days postinjection random-ized into twogroups.One groupwas locally irradiated to the head
with 10 Gy. A small cohort of mice was also sacrificed at the time
of irradiation and the presence of tumor lesionswas confirmedby
H&E in all animals analyzed (5/5) in both genetic backgrounds
(data not shown). The exposure to IR resulted in a prolonged
survival in the Ink4a/Arf/ (approximately 15 days, p = 0.0002
log rank) but did not have any effect on the Chk2/ mice. These
data are consistent with the lower apoptotic index and higher
proliferation rate that we observed in Ntv-a Chk2/ tumor-
bearing mice exposed to IR, strongly suggesting that Chk2 plays
an important role in the radiation response in glioma.
Cell-Cycle Checkpoint Defects in Chk2 Null Glioma
Neurospheres and Normal Neuronal Stem Cells of
Immature Postnatal Mice
We further investigated the integrity of cell-cycle checkpoints in
Chk2 null gliomas using tumor neurospheres (tumor cells
cultured in the bFGF and EGF) derived from primary glioblas-
tomas. These cell cultures more closely resemble the phenotype
and genotype of the tumors than do serum cultured cell lines
(Lee et al., 2006). Moreover, GBM cells propagated as
neurospheres (both from human and mouse) contain stem-like
subpopulations that are able to generate tumors when
transplanted into mice, and exhibit a more accurate infiltrating
growth pattern seen in primary tumors (Bleau et al., 2009; Galli
et al., 2004). As we have previously shown (Bleau et al., 2009;
Charles et al., 2010), tumor neurospheres derived from N-tva
mice injected with RCAS/PDGF, when transplanted into synge-
neic mice, are able to generate tumors that histopathologically
resemble the primary tumors (Figure S2A), suggesting that they
could be used as a reliable in vitro tumor model for our studies.
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Figure 4. Cell-Cycle Checkpoints Are Defective in
Chk2 Null Tumor Neurospheres and Normal
Neuronal Stem Cells (NSCs)
(A and B) (A) The S-phase ratios (%BrdU-positive of
treated/average %BrdU-positive untreated) and (B) the
mitotic ratios (%pH3-positive of treated /average %pH3-
positive untreated) of IR-treated tumor neurospheres (18
and 3 hr posttreatment, respectively) are plotted. The
wedges denote increasing ionizing radiation (IR) doses
(0, 1, 5, or 10 Gy).
(C) Mitotic ratios of 10 Gy IR-treated tumor neurospheres
at the indicated time points.
(D) S-phase ratios of mock (white bar) or 10 Gy IR-treated
(black bar) NSCs of the indicated genotype. See also Fig-
ure S2.
(E) Mitotic ratios of 10 Gy IR-treated NSCs at the indicated
time points. Results are presented as mean ± SD from
a representative of two experiments, performed in tripli-
cate.
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DNA Damage Response and GliomagenesisThe G1/S checkpoint, which prevents cells from entering
S phase, is predominantly regulated by p53 (Kuerbitz et al.,
1992) and is defective in ATM null cells (Xu and Baltimore,
1996). Despite its well-known function in ATM-dependent
IR-induced p53 activation, the role of Chk2 in the G1/S check-
point is still controversial (Hirao et al., 2002; Jack et al., 2002;
Stracker et al., 2008; Takai et al., 2002). To examine the G1/S
checkpoint, glioma neurospheres were exposed to increasing
doses of IR (1, 5, and 10 Gy), and the percentage of cells in
S phase 18 hr posttreatment was measured by BrdU incorpora-
tion. In the Ink4a/Arf / glioma neurospheres, the percentage of
BrdU-positive cells at the highest IR dose (10 Gy) dropped to
approximately 10% of the mock irradiated cells (Figure 4A).
The same result was obtained with wild-type tumor neuro-
spheres (data not shown). By contrast, over 60% of the cells
was still incorporating BrdU in Chk2/ glioma neurospheres,
clearly indicating a defect in the G1/S checkpoint in these cells.
As expected p53/ glioma neurospheres are completely devoid
of such a checkpoint andmaintain the ability to incorporate BrdU
even at the highest radiation dose analyzed (Figure 4A).
The role of Chk2 in the G2/M checkpoint has also been
debated (Hirao et al., 2000, 2002; Takai et al., 2002).
As described above, Chk2 null gliomas exposed to IR show
a higher mitotic index (measured as percentage of pH3-positive
cells) than either wild-type or Ink4a/Arf null gliomas (Figure 3B),
suggesting a possible defect in the G2/M checkpoint. To analyze
the integrity of the G2/M checkpoint, glioma neurospheres were
exposed to increasing doses of IR (1, 5, and 10 Gy), and theCancer Cell 18, 619–percentage of pH3-positive cells was measured
3 hr posttreatment. Ink4a/Arf /, Chk2/, and
p53/ cells showed similar kinetics in the
reduction of pH3-positive cells, becoming
almost undetectable at 10 Gy IR (Figure 4B).
These results are consistent with our in vivo
observations in glioma-bearing mice exposed
to IR, suggesting that the activation of the
G2/M checkpoint was intact both in vitro and
in vivo. Moreover, while all the cells in the
Chk2/ glioma neurospheres cultures, and to
a similar extent the p53/ cells, re-entered thecell cycle by 24 hr posttreatment, only 5% of the cells of the
Ink4a/Arf / (Figure 4C) or wild-type (data not shown) did so.
These data clearly indicate that Chk2 is required for the mainte-
nance of the G2/M checkpoint in gliomas, but not for its activa-
tion, either in vitro or in vivo.
In order to exclude the possibility that the defects in cell-cycle
checkpoints in Chk2 null glioma and tumor neurospheres were
due to additional mutations acquired during the tumor formation
or in vitro cell culture artifacts (caused by multiple passages of
tumor cells), we analyzed the integrity of checkpoints in freshly
isolated neuronal stem cells (NSCs), derived from wild-type,
Chk2/, and Ink4a/Arf / newborn mice. The G1/S and G2/M
checkpoints were tested in these cultures by BrdU incorporation
and pH3-positive cell sorting. Eighteen hours after exposure to
10 Gy IR in both wild-type and Ink4a/Arf / resulted in less
than 10% of cells incorporating BrdU, while 60% of Chk2/
NSCs were still synthesizing DNA (Figure 4D; Figure S2B–
S2D). Furthermore, all genotypes responded to 10 Gy IR by
a 90%–95% reduction of pH3-positive cells, but only the
Chk2/ NSCs re-entered the cell cycle by 24 hr after exposure
to IR (Figure 4E). These data indicate that Chk2 is required for the
activation of the G1/S and for the maintenance of G2/M check-
point in the neuronal stem cell compartment of postnatal mice.
Aberrant Constitutive Activation of DDR in GBM
Specimens
Markers of a constitutively active DDR have been described
in multiple human epithelial tumors (Bartkova et al., 2005;629, December 14, 2010 ª2010 Elsevier Inc. 623
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Figure 5. Constitutive Activation of DDR in Human GBM
(A) Summary of IHC results. gH2AX and Chk2 pT68 were quantified as described in Experimental Procedures. 53BP1 staining was scored as follow: weak (+),
moderate (++), and strong (+++). n/a = not applicable (absence of pseudopalisades necrosis).
(B) Plot of the percentage of total gH2AX and Chk2 pT68-positive cells.
(C–H) Micrographs of pseudopalisading necrosis of GBMs stained with H&E, anti-HIF1a, anti Ki-67, anti- gH2AX, anti-Chk2 pT68, and anti-53bp1, respectively
(see also Figure S3). Inset in (E) shows nuclear accumulation of HIF1a in cells of the pseudopalisades rim. Scale bars, 100 mm.
(I) Plot of the percentage of positive cells in tumor bulk and pseudopalisades for gH2AX (top panel) and for Chk2 pT68 (bottom panel).**p < 0.01 and *p < 0.05 (see
text for more details).
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shown to be absent in other malignant lesions, such as testicular
germ cell tumors (Bartkova et al., 2007). To analyze a possible
aberrant activation of the DDR in GBMs specimens, we per-
formed IHC on formalin-fixed, paraffin embedded tissues, using
antibodies against phosphorylated S139 of histone H2AX
(gH2AX) and phosphorylated T68 Chk2 (Chk2 pT68). A granular
(focal) nuclear staining pattern of 53BP1, indicating the formation
of DNA double-strand breaks, was also considered a marker
(53BP1 foci) for an activated DDR (see Figure S3A for represen-
tative micrographs).
We stained 14 newly diagnosed GBMs samples from patients
not previously exposed to radiation or chemotherapy. Approxi-
mately 80% (11/14) of the samples showed nuclear gH2AX stain-
ing in a small fraction of cells, ranging from 0.5% to 8.4% of total624 Cancer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier Inccells (Figure 5A). No gH2AX accumulation was found in ten
normal tissue samples of different area of the brain (data not
shown). Chk2 pT68 was detected in a lower percentage of
tumors than gH2AX, approximately 60% (8/14), and in a number
of cells varying from 0.2% to 2.5% (Figures 5A and 5B)
(p = 0.0069, two sided Student’s paired t test on the percentage
of gH2AX cells versus percentage of Chk2 pT68 cells). Consis-
tent with the gH2AX observations, no Chk2 pT68 staining was
present in normal tissues (data not shown). Moreover, 14% of
tumors analyzed (2/14) presented nuclear 53BP1 foci and
notably, those samples were the ones with a high percentage
of gH2AX-positive cells (Figure 5A).
Several tumors analyzed presented regions of pseudopalisad-
ing necrosis. These structures, which represent the histologic
definition of GBMs, are characterized by hyper cellular area.
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previous reports (Brat et al., 2004), pseudopalisading cells in
these tumors showed a lower proliferating index (measured by
Ki-67 staining) as compared with the tumor bulk and also
showed nuclear accumulation of HIF1-a (Figures 5D and 5E),
indicating higher hypoxic levels in these cells. Although only
a small percentage of total number of cells presented an
activated DDR, when compared with the adjacent tumor cells,
the pseudopalisade rim showed a significantly higher
percentage of gH2AX (p = 0.0071, two-sided paired Student’s
t test) (Figures 5F and 5I top panel; Figure S3B) and of Chk2
pT68-positive cells (p = 0.0297, two-sided paired Student’s
t test) (Figures 5G and 5I, bottom panel; Figure S3B). These
data suggest that the DDR activation in GBM may be hypoxia
related.
DISCUSSION
ATM/CHEK2 Alteration in Human Gliomas
It has been previously proposed that the DDR acts as an induc-
ible barrier to tumorigenesis, and defects in elements of the DDR
have been associated with different human pathologies,
including cancer (Jackson and Bartek, 2009). Here we show
that the ATM/Chk2/p53 cascade, key components of the DDR,
exert an important tumor suppressor activity in the brain.
Mutations of the ATM gene are responsible for the ataxia-
telangiectasia (A-T) disease, an autosomal recessive disorder
that is characterized by early onset progressive cerebellar ataxia
and high incidence of lymphoid tumors (approximately 30%)
(for review see, Lavin, 2008). With regard to the central nervous
system tumors, some cases of primary brain tumors, including
gliomas, have also been reported in A-T patients (Miyagi et al.,
1995). CHEK2, one of the main ATM downstream effectors,
has been proposed to act as a multiorgan cancer susceptibility
gene (Cybulski et al., 2004). While mutations in CHEK2 do not
appear to account for the cancer-predisposing Li-Fraumeni
Syndrome as originally hypothesized, rare germline mutations
have been identified in several types of familial cancers
(prostate, breast, ovarian, colorectal, kidney, thyroid, bladder
cancers, and leukemias) and rare somatic mutations have also
been detected in a variety of human tumors (Antoni et al.,
2007). Previous studies reported no (Ino et al., 2000) or low
frequency of CHEK2 mutations (approximately 6%) (Sallinen
et al., 2005) in small cohorts of human glioma patients. More-
over, Wang and colleagues recently reported a significant down-
regulation of CHEK2 expression in a group of glioma specimen
compared with normal control, and this reduction in expression
was partially due to promoter methylation (Wang et al., 2009).
Our analysis of TCGA showed that a high number of patients
(22%) present single copy loss of the chromosomal region con-
taining CHEK2, with a significant reduction of CHEK2 mRNA
expression, suggesting that it might represent an important
tumor suppressor in a subset of glioma patients. Evaluation of
CHEK2 mutations by resequencing, including TCGA data, is
complicated by the presence of paralogs in the genome
assembly. Therefore, although five CHEK2 somatic missense
mutations have been reported in the TCGA data set (Table S1),
at this time we consider the mutation rate to be undetermined.
We further observed that in human gliomas, CHEK2 alterationsCancould co-occur with TP53 alterations (either TP53 mutations/
loss or MDM2 amplifications). This finding correlates with our
mouse studies that demonstrate that although p53 and Chk2
are epistatic in terms of glioma-free survival, loss of Chk2 could
lead to the development of more aggressive gliomas when
combined with p53 defects.
The ATM/Chk2/p53 Axis Suppress PDGF-Induced
Glioma Formation in Mice
PDGF-pathway activation, that is primarily ligand-driven, has
been recently shown to represent one of the three major signal
transduction pathways that characterize different GBM
subclasses, together with EGFR activation and NF1 loss
(Brennan et al., 2009; Verhaak et al., 2010). The RCAS/PDGF
glioma model has been extensively used to study diverse
aspects of glioma biology and has been shown to produce
tumors that closely resemble human GBMs (Huse and Holland,
2009; Hambardzumyan et al., 2008). Using this somatic cell
gene transfer methodology, we showed that the ATM/Chk2/
p53 pathway is required for glioma tumor suppression in mice,
and loss of any of those genes both shortens tumor latency
and leads to a more aggressive phenotype, increasing the
frequency of high-grade tumors (GBMs). The role of the ATM/
Chk2/p53 pathway on tumor suppression can be attributed to
its influence on the induction of apoptosis as well as on the
regulation of DNA damage dependent checkpoints. Genetic
contexts in which apoptosis and checkpoints are individually
defective are not strongly predisposed to malignancy. For
example, p53515C/515Cmice are defective in apoptosis, but retain
p53-dependent G1/S checkpoint functions. Relative to p53/
mice, in which both apoptosis and G1/S checkpoint control
are abrogated, tumor latency in p53515C/515C mice is markedly
increased (Liu et al., 2004). Similarly, in Mre11ATLD1/ATLD1
Chk2/ mice, p53-dependent apoptosis is abrogated, but G1/
S checkpoint control is largely intact (Stracker et al., 2008).
Hence, concomitant loss of checkpoint control and apoptotic
regulation appears to undermine tumor suppression to a signifi-
cantly greater extent than disruption of either function singly. The
clear dependence on Chk2 for G1/S checkpoint control in NSCs
contrasts the situation observed in other Chk2/ murine cell
types. This unique dependence on Chk2 has two general impli-
cations. First, it supports the view that increased susceptibility
to GBM in Chk2/ mice may reflect the tumor suppressive
effects of the G1/S checkpoint in addition to Chk20s role in
promoting apoptosis. Presumably, both functions are required
to mitigate the oncogenic effects of spontaneous DNA damage
in developing GBM. Second, the data further support the view
that radioresistance in Chk2 proficient GBM may reflect the
protective effects of the G1/S checkpoint.
Activation of DDR in GBMs Correlates with Hypoxia
The current model of DDR activation in human tumors proposes
that the activation of DNA damage checkpoints acts as a barrier
against progression of tumors beyond their early, preinvasive
stage, and represent a strong selective pressure for mutation
in p53 or other DDR components (Bartek et al., 2007). In agree-
ment with this hypothesis, Bartkova and colleagues have shown
in a recent report a more pronounced DDR activation in low-
grade glioma than what they observed in a set of GBM specimencer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier Inc. 625
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pressure to lose DDR activity in the progression from low- to
high-grade tumors. Constitutive activation and aberrant loss of
DDR components has been shown in other tumor types, such
as lung and breast cancer (Bartkova et al., 2007). In GBM tissues,
we observed a small percentage of cells presenting markers of
an active DDR (such as gH2AX and Chk2 pT68), but notably
this activation correlates with region of hypoxia. H2AX is phos-
phorylated in a context-dependent manner by at least three
different kinases (ATM, ATR, and DNA-PK) of the PI3K-related
kinase family (PI3KK) (Hammond et al., 2003; Stiff et al., 2004;
Ward and Chen, 2001). Although our TCGA analysis showed
copy number alterations in either ATM or ATR, we cannot
exclude that the activity of these kinases is partially maintained
or, alternatively, partially compensated by other PI3KK kinases,
at least to some extent. This residual kinase activitymight also be
responsible for the phosphorylation of Chk2, that per se is homo-
zygously lost in only 0.35% (1/272) of the patients in the TCGA
analysis (data not shown). Although it appears there is a selective
pressure to reduce the activity of the ATM/Chk2 kinases in GBM,
this pathway might still maintain the ability to be partially acti-
vated under higher cellular stress condition such as hypoxia.
Proof of activation of the ATM/ATR signaling pathways by
hypoxia has been recently reported in vitro (Bencokova et al.,
2009; Freiberg et al., 2006; Gibson et al., 2005) and it was previ-
ously hypothesized to happen in human tumors (Bartkova et al.,
2005). ATM can be phosphorylated and activated during hypoxia
in the absence of DNA damage as detected by either comet
assay or 53BP1 focus formation (Freiberg et al., 2006). Subse-
quently Chk2 is also phosphorylated and activated in an ATM-
dependent manner (Bencokova et al., 2009; Gibson et al.,
2006). Interestingly, cells in the pseudopalisade rim do not
show focal staining of 53BP1, underlining the absence of detect-
able DNA damage. By contrast, 53BP1 is much less expressed
in those cells as compared with the tumor bulk (Figures 5A and
5H; Figure S3B). Several DNA repair factors (such as RAD51,
BRCA1 and 53BP1) are downregulated in hypoxic conditions
in vitro, and it has been proposed that this could lead to genomic
instability (Bencokova et al., 2009; Bristow and Hill, 2008).
53BP1 is an important component of both the DDR and also of
the DNA repair process. A reduction in 53BP1 levels is sufficient
to compromise the maintenance of chromosomal structure and
number (Ward et al., 2005); therefore, low levels of 53BP1 might
contribute to hypoxia-induced genomic instability in gliomas.
Clinical Perspective
Standard therapy for GBMs includes resection of the tumor
mass followed by concurrent radiotherapy and chemotherapy
using the alkylating agent temozolomide (TMZ). Nonetheless,
many GBM patients are refractory to radiotherapy and chemo-
therapy treatments. Understanding the mechanism of this resis-
tance will be instrumental for the development of new treatment
modalities for gliomas. Previous studies reported that Chk2 gene
silencing prevented a TMZ-induced G2 arrest (Hirose et al.,
2005), whereas pharmacological targeting of Chk1 increased
TMZ cytotoxicity (Hirose et al., 2001). Moreover, dual pharmaco-
logical inhibition of Chk1 and Chk2 kinases has been shown to
revert the radioresistance of a subpopulation of glioma cells
in vitro (Bao et al., 2006).626 Cancer Cell 18, 619–629, December 14, 2010 ª2010 Elsevier IncIn this report, we demonstrate that genetic loss of Chk2
protects glioma cells from IR-induced apoptosis in vivo and
prevents the activation of DNA damage-induced cell-cycle
checkpoints. Most importantly, this lack of response to IR also
abolishes the IR-mediated survival benefit observed in Chk2-
proficient glioma-bearing mice. Our results somehow differ
from what Bao and colleagues had previously shown
(Bao et al., 2006). In their experimental settings, they observed
an increase in radiosensitivity of glioma stem-like cells upon
treatment with the sponge alkaloid debromohymenialdisine
(DBH) that inhibits both the Chk1 and Chk2 kinases. It is possible
that the phenotypes they observed are primary related to the
DBH effect on Chk1 activity. Even though our data point to an in-
dispensible role of Chk2 in IR response in gliomas, we believe
that it might be too early to conclude whether this evidence
can be generalized to other components of the DDR, considering
the high complexity of this signaling pathway. Our data do indi-
cate that specific pharmacological inhibition of Chk2 may not
be an effective treatment for glioma patients, though genetic or
pharmacological inactivation of other elements of the DDR,
such as Chk1, might results in increased sensitivity to IR or other
treatment modalities that inflict DNA damage.
EXPERIMENTAL PROCEDURES
Human Tissue Specimens
Following informed consent, tumor samples classified as GBM based on
World Health Organization (WHO) criteria were obtained from patients under-
going surgical treatment in accordance with Memorial Sloan Kettering Cancer
Center Review Board. Tissues were processed as described below. Normal
human brain tissues were purchased fromMillipore (#TMA3001-4) and Analyt-
ical Biological Services (Wilmington, DE).
Histology, Immunohistochemistry, and TUNEL Assay
Tissues were fixed in 10% neutral buffered formalin and subsequently
embedded in paraffin, following standard procedures. Immunohistochemical
staining was performed on 5 mmsections of formalin-fixed/paraffin-embedded
tissues, using a Discovery XT automated staining processor (Ventana Medical
Systems, Inc.). The following antibodies were diluted in PBS 2%BSA as follow:
gH2AX (Upstate, #07-164) 1:100, anti-phospho Chk2 (Thr68) (Cell Signaling,
#2661) 1:100, anti-53bp1 (Novus, #NB100-304) 1:800, anti-HIF1a (Chemicon,
#AB3883) 1:100, Ki-67 (Dako, #M7240) 1:100, anti-GFAP (Dako, #Z0334)
1:2000, anti-Olig2 (Millipore, #AB9610) 1:400, anti-phospho-Histone H3
(Ser10) (Millipore, #06-750) 1:800. Images from each tumor were acquired
with a Nikon Eclipse E400 microscope connected to a Nikon Digital Slight
camera system.
The TUNEL assay was performed with a terminal transferase recombinant
kit (Roche, #333-574-001) on an automated staining processor (Discovery
XT, Ventana Medical Systems, Inc.).
For quantification of immunohistochemical and TUNEL staining, images
were acquired with a Zeiss Imager Z1 microscope using an automated stage,
and subsequently analyzed using the HistoQuest image analysis software
(Tissue Gnostics, Austria). Briefly, the HistoQuest software use a specific algo-
rithm to identify the nucleus of each cells, it measures the DAB intensity stain-
ing (brown nuclei) and gives you the percentage of positive cells (brown nuclei/
total nuclei). With exception of the necrotic cells inside the pseudopalisades,
no TUNEL-positive cells were detected in the mock irradiated samples (data
not shown). Because the number and the size of the pseudopalisades highly
variable in different tumors, these areas were excluded from the quantification
of TUNEL-positive cells in the irradiated samples.
Mice
Nestin-tva mice have been previously described (Holland et al., 1998). p53/
mice were obtained from The Jackson Laboratory. All animal experiments.
Cancer Cell
DNA Damage Response and Gliomagenesiswere done in accordance with protocols approved by the Institutional Animal
Care and Use Committee of Memorial Sloan-Kettering Cancer Center and fol-
lowed National Institutes of Health guidelines for animal welfare. Genotyping
primers will be provided on request.
Cell Culture, Transfection, and Neurosphere Preparation
DF1 cells (ATCC) were grown at 39C in DMEM (ATCC) containing 10% FBS
(PAA, The Cell Culture Company, USA). DF1 cells were transfected with the
RCAS-PDGF viral plasmid, using Fugene 6 Transfection reagent (Roche),
accordingly to manufacturer’s protocol.
Mouse tumor neurospheres and normal neuronal stem cells (derived from
the whole brain of newborn mice [p1–p3]) were prepared by enzymatic
dissociation and low-speed centrifugations as previously described (Bleau
et al., 2008). Normal brain cortex or tumors were dissected and collected in
13 Earle’s balanced salt solution (EBSS) (GIBCO, USA). The tissue was enzy-
matically digested in Earle’s balanced salt solution containing 12%papain and
10 mg/ml DNase at 37C for 15 min, with subsequent inactivation using
ovomucoid (1 mg/ml) (Worthington, Lakewood, NJ, USA). The cell suspension
was consecutively washed and resuspended to obtain a single cell suspen-
sion. For neurosphere culture, cells were seeded at 53 104 cells/ml and grown
in neurosphere medium from NeuroCult (Stem Cell Technologies, Inc.,
Vancouver, BC, Canada) according to the manufacturer. Themedium consists
in NSC Basal medium, mouse NSC Proliferation Supplements, 10 ng/ml EGF,
20 ng/ml basic-FGF, and 1 mg/ml Heparin. Fresh medium was replaced into
the cultures every 48–72 hr, and tumor stem-like cells were propagated as
neurospheres by serial dilution.
Generation of Murine Gliomas
Ntv-a mice, and procedures for RCAS-mediated gliomagenesis have been
described previously (Holland et al., 1998; Holland and Varmus, 1998). After
injection of the RCAS-PDGF virus during the newborn period, mice were
aged until they developed symptoms of disease (lethargy, poor grooming,
weight loss, macrocephaly).
Cell-Cycle Analysis
Cell-cycle checkpoints analysis were performed as described (Theunissen
and Petrini, 2006). For the G1/S checkpoint studies, BrdU (10 mM) was added
in the culture medium for 2 hr, before ethanol fixation. Staining was performed
using an anti-BrdU-FITC (BD PharMingen). For the G2/M checkpoint studies,
we used the anti-phospho-Histone H3 (Ser10) described above. Samples
were acquired using a Becton Dickinson FACSCalibur flow cytometer and
analyzed with the Flowjo software.
Radiation
Neurospheres cultures were irradiated using a Cs-137 source (dose rate
200 cGy/min- Shepherd Mark-1). Tumor-bearing mice were irradiated using
a Cs-137 source (Gammacell 40 Exactor, MDS Nordion). For survival analysis,
mice were sedated with ketamine and xylazine, and irradiation of the head was
done using a X-RAD 320 from Precision X-Ray at 115 cGy/min (the rest of the
mouse was shielded with a lead jig).
Statistical Analysis
Results were subjected to statistical analysis using GraphPad Prism v5.0 soft-
ware. Survival curves were analyzed using the Kaplan-Meier method, with
groups compared by respective median survival of number of days taken to
reach 50% morbidity; log rank p value was measured using the Mantel-Cox
test. Two-tailed t test has been used for other analysis.
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